Longbow Finance Sa Vertex Pharmaceuticals Inc Transaction History

Longbow Finance Sa

$915 Billion
Q4 2024

A detailed history of Longbow Finance Sa transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Longbow Finance Sa holds 22,699 shares of VRTX stock, worth $11.3 Million. This represents 1.0% of its overall portfolio holdings.

Number of Shares

22,699

Previous 6,671 240.26%

Holding current value

$11.3 Million

Previous $3.1 Billion 194.63%

% of portfolio

1.0%

Previous 0.33%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 04, 2025	BUY	$396.64 - $516.74 $6.36 Million - $8.28 Million	16,028 Added 240.26%	22,699 $9.14 Billion
Q3 2024 Nov 12, 2024	SELL	$460.0 - $505.78 $3.66 Million - $4.02 Million	-7,954 Reduced 54.39%	6,671 $3.1 Billion
Q2 2024 Aug 12, 2024	SELL	$392.81 - $485.53 $344,887 - $426,295	-878 Reduced 5.66%	14,625 $6.86 Billion
Q1 2024 Apr 30, 2024	SELL	$407.69 - $446.08 $16.7 Million - $18.3 Million	-40,991 Reduced 72.56%	15,503 $6.48 Billion
Q4 2023 Feb 08, 2024	BUY	$343.0 - $410.68 $893,515 - $1.07 Million	2,605 Added 4.83%	56,494 $23 Billion
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $4.2 Million - $4.51 Million	12,433 Added 29.99%	53,889 $18.7 Billion
Q2 2023 Nov 13, 2023	SELL	$314.42 - $351.91 $7,860 - $8,797	-25 Reduced 0.06%	41,456 $14.6 Billion
Q1 2023 May 12, 2023	BUY	$283.23 - $323.1 $118,390 - $135,055	418 Added 1.02%	41,481 $13.1 Billion
Q4 2022 Feb 13, 2023	BUY	$285.76 - $321.48 $11.7 Million - $13.2 Million	41,063 New	41,063 $11.9 Billion

Others Institutions Holding VRTX

# of Institutions

1,760

Shares Held

228M

Call Options Held

1.63M

Put Options Held

1.47M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $128B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Longbow Finance Sa, based on Form 13F filings with the SEC.

News

Stay updated on Longbow Finance Sa with notifications on news.

Account

Longbow Finance Sa Vertex Pharmaceuticals Inc Transaction History